The Management and Imaging of Vestibular Schwannomas

E.P. Lin and B.T. Crane

doi: https://doi.org/10.3174/ajnr.A5213
http://www.ajnr.org/content/38/11/2034

This information is current as of September 21, 2023.
The Management and Imaging of Vestibular Schwannomas

E.P. Lin and B.T. Crane

SUMMARY: Vestibular schwannomas are the most common cerebellopontine angle tumor. During the past century, the management goals of vestibular schwannomas have shifted from total resection to functional preservation. Current treatment options include surgical resection, stereotactic radiosurgery, and observation. Imaging has become a crucial part of the initial screening, evaluation, and follow-up assessment of vestibular schwannomas. Recognizing and understanding the management objectives, various treatment modalities, expected posttreatment findings, and complications allows the radiologist to play an essential role in a multidisciplinary team by providing key findings relevant to treatment planning and outcome assessment. The authors provide a comprehensive discussion of the surgical management, role of radiation therapy and observation, imaging differential, and pre- and posttreatment imaging findings of vestibular schwannomas.

ABBREVIATIONS:
- AAO-HNS: American Academy of Otolaryngology-Head and Neck Surgery
- CN: cranial nerve
- CPA: cerebellopontine angle
- 3D SS-GRE: volumetrically acquired steady-state gradient-echo
- IAC: internal auditory canal
- MF: middle fossa craniotomy
- PF: posterior fossa
- RS: retrosigmoid craniotomy
- SRS: stereotactic radiosurgery
- TL: translabyrinthine craniotomy
- VS: vestibular schwannoma

Vestibular schwannomas (VSs) are benign neoplasms of the nerve sheath and account for 6%–8% of all intracranial tumors and 80% of cerebellopontine angle (CPA) tumors.1 VSs may remain within the internal auditory canal (IAC) or extend into the CPA. Symptoms are typically related to compression of adjacent cranial nerves (CNs), brain stem, or posterior fossa (PF) structures.

Imaging plays a central role in the screening and initial and follow-up assessment of VSs. Imaging can often differentiate VS from other entities such as facial nerve schwannoma, meningioma, epidermoid cyst, arachnoid cyst, aneurysm, and metastasis.2 MR imaging is the preferred technique and can provide exquisite tumor characterization, surgical planning, and posttherapeutic evaluation.3-5 Contrast-enhanced CT of the temporal bones can serve as an alternative if the patient cannot undergo MR imaging.

The goals of VS management have shifted from total resection to functional preservation, particularly when the entire tumor cannot be safely resected with respect to cranial nerve preservation.6,7 Studies have revealed suboptimal postsurgical facial nerve function in gross total resection of large VSs.8,9 Depending on many factors, including patient age, tumor size and growth, and symptomatology, patients can choose surgery, radiation, or conservative management. Patients with neurofibromatosis type 2, which is characterized by bilateral VSs, other schwannomas, meningiomas, ependymomas, and ocular abnormalities, are managed differently than those with sporadic unilateral VSs10 and will not be further discussed due to the scope of this topic.

Advances in surgical management of VS during the past century have defined lateral skull base approaches that are now applied in the management of other PF and skull base pathologies. Each approach offers different surgical exposures, benefits, and disadvantages. Stereotactic radiosurgery (SRS) is an acceptable option, with similar rates of tumor control and a low risk for permanent facial nerve palsy. Observation is a reasonable option for smaller tumors, older patients, and those with major comorbidities.

This article will review the treatment objectives, surgical approaches, and expected posttreatment findings and complications of VS management. Knowledge of these advances enhances the radiologist’s ability to participate in a multidisciplinary team.
by providing key information relevant to the treatment planning and outcome.

**Background**

VS, often referred to as “acoustic neuroma,” most commonly originates from the vestibular division of the vestibulocochlear nerve sheath, often at the transition from central to peripheral myelin near the vestibular ganglion at the IAC fundus.

Inactivation of the neurofibromin 2 gene has been implicated in sporadic and neurofibromatosis type 2 VS. This gene is located on chromosome 22 and produces schwannomin (merlin), a tumor-suppressor cell membrane–related protein. Perineural elements of Schwann cells, with areas of dense (Antoni A) and sparse (Antoni B) cellularity, are found histopathologically. Immunohistochemical staining is typically positive for S-100 protein.

VS presents at a median age of 50 years and is unilateral in >90% of patients, with an equal incidence on the left and right. Symptomatology is often related to cranial neuropathies. Patients more often present with chronic asymmetric sensorineural hearing loss than tinnitus or unsteadiness. True vertigo, sudden hearing loss, facial pain, numbness, and weakness are uncommon due to slow tumor growth. Sensorineural hearing loss is confirmed by audiometry and brain stem–evoked response audiometry, with findings that are abnormal in >90%–95% of patients with VS.

**Historical Perspective**

Charles McBurney performed the first suboccipital plate removal in 1891, though the patient died soon after. A few years later, Sir Charles Ballance in England was the first to successfully remove a VS via a suboccipital plate and blunt dissection of a CPA mass.

Surgical outcome, in general, remained poor in the late 1800s, with a surgical mortality rate of 80% and high postoperative morbidity.

By observing the radiographic properties of bowel gas, Walter Dandy injected air into the subarachnoid spaces, creating the first pneumoencephalographic images in the early 1900s. Pneumoencephalography allowed the localization of intracranial masses by observing the mass effect on the ventricles and the direction of the midline shift.

Advances in neurosurgery in the early 1900s led to a decrease in surgical mortality to 20%. Harvey Cushing promoted a bilateral suboccipital approach and removal of the tumor core while leaving the tumor capsule in place to improve CN preservation.

In 1961, William House introduced the operative microscope in temporal bone surgeries, allowing exquisite visualization and improved preservation of the facial nerve. William House fostered collaboration with the neurosurgeon William Hitselberger, establishing a multidisciplinary approach to VS resections. William House re-introduced the translabyrinthine approach as an option for patients with unserviceable hearing.

In 1979, Tomas Delgado performed the first intraoperative CN monitoring, which improved CN preservation.

During the same period, Lars Leksell in Sweden invented the gamma knife in 1968 and performed the first SRS on a VS in 1969. SRS was later confirmed as an effective alternative to surgery in the treatment of VS.

Radiographically, positive-contrast cisternography in the 1960s improved delineation of PF structures. Polytome-pantopaque allowed depiction of even smaller intracanalicular VSs. The advent of cross-sectional imaging in the 1970s now provides noninvasive means of detecting and evaluating small VSs.

**Natural History of VS**

More than half of all VSs grow at an average of 2–4 mm/year, whereas <10% regress. One study revealed that extrameatal tumors (28.9%) were more likely to grow compared with intrameatal tumors (17%) and a larger percentage of tumors grew early on after detection. A VS of >2 cm is more likely to grow compared with a smaller VS. Growth rates of >2 mm/year are associated with decreased rates of hearing preservation compared with slower growth rates.

**Surgical Management of VS**

Surgical objectives have shifted from total resection to long-term functional preservation. Subtotal resection followed by observation or SRS, particularly for a large VS, can achieve long-term tumor control with improved CN preservation. In general, a small-to-medium VS of <3 cm is managed differently from a large VS because surgery is often favored over SRS for a large VS. While some investigators have experience in successfully treating large VSs with SRS, others believe that SRS may risk compressive ischemia of CN VII and brain stem compression in the treatment of a large VS. The optimal treatment of a VS, particularly a small-to-medium one, remains controversial, and treatment technique preference will vary from center to center.

Gross total resection is offered to younger patients with persistent dizziness, patients with small anatomically favorable tumors and good hearing, cystic tumors, and larger tumors with symptoms related to mass effect. Surgery, as opposed to SRS, provides a definitive histopathologic diagnosis. Due to the postradiation effects on tissue, SRS following surgical resection is more favorable than surgical resection following SRS. Surgery, however, is associated with a greater risk of permanent facial nerve palsy compared with SRS. Other risks of surgical resection include iatrogenic hearing loss, CSF leak, meningitis, headache, and anesthesia-related complications. Following gross total resection, the 5-year recurrence rate of VS has been reported as up to 10%. The 10-year tumor control rates for gross total and subtotal resection are 78% and 82%, respectively.

**Surgical Approaches**

VS may be approached by a translabyrinthine (TL), retrosigmoid (RS), or middle fossa (MF) craniotomy. The indications, advantages, and disadvantages of each are summarized in Table 1.

**Translabyrinthine Cranietomy**

The TL is a posterior approach through the mastoid temporal bone, anterior to the sigmoid sinus (Fig 1). Following a simple mastoidectomy, the vertical facial nerve canal is skeletonized and a labyrinthectomy is performed, allowing access to the IAC behind the vestibule (Fig 1). Access to the CPA can be gained by removing bone posterior to the porus acusticus. While one performs facial nerve monitoring, the tumor is debulked and micro-
dissected. The craniotomy is closed by placing the temporalis fascia at the aditus ad antrum and abdominal fat packing within the mastoidectomy defect. Fat is preferred to muscle because fat is easily obtainable and associated with less morbidity. The fat signal can be advantageously suppressed on follow-up contrast-enhanced MR imaging (Fig 2).

The TL allows adequate exposure of the IAC and CPA, and it may be performed with or without cerebellar retraction. Intraoperative images just before (B) and following (C) the labyrinthectomy demonstrate exposure to the intracanalicular vestibular schwannoma. PA indicates porus acusticus. A is reproduced with permission from the University of Rochester.

**Table 1: Indications, benefits, and disadvantages of lateral skull base approaches for VS resection**

<table>
<thead>
<tr>
<th>Approach</th>
<th>Indications</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translabyrinthine</td>
<td>Unserviceable hearing; any IAC or CPA VS</td>
<td>Minimal brain retraction</td>
<td>Complete hearing loss; difficult approach for CPA VS ventral to porus acusticus; risk for facial nerve injury</td>
</tr>
<tr>
<td>Retrosigmoid</td>
<td>VS with large CPA component; medial IAC VS</td>
<td>Panoramic CPA exposure; better facial nerve and hearing preservation for medial VS</td>
<td>Limited access to lateral IAC; potential for cerebellar and brain stem injury</td>
</tr>
<tr>
<td>Middle Fossa</td>
<td>Small lateral IAC VS (&lt;0.5 cm); small medial IAC VS with &lt;1 cm CPA component</td>
<td>Better exposure, lateral IAC</td>
<td>Limited PF access; temporal lobe retraction; risk for facial nerve injury</td>
</tr>
</tbody>
</table>

**FIG 1.** Axial illustration (A) of a translabyrinthine craniotomy demonstrates exposure of the IAC and CPA, and it may be performed with or without cerebellar retraction. Intraoperative images just before (B) and following (C) the labyrinthectomy demonstrate exposure to the intracanalicular vestibular schwannoma. PA indicates porus acusticus. A is reproduced with permission from the University of Rochester.

**FIG 2.** Precontrast axial TIWI (A) and postcontrast axial TIWI with fat-suppression (B) demonstrate typical postoperative findings following a translabyrinthine craniotomy, with abdominal fat packing within the mastoidectomy defect (asterisk). Linear enhancement along the mastoidectomy bed reflects postsurgical changes without evidence of recurrent tumor within the IAC.

FIG 1. Axial illustration (A) of a translabyrinthine craniotomy demonstrates exposure of the IAC and CPA, and it may be performed with or without cerebellar retraction. Intraoperative images just before (B) and following (C) the labyrinthectomy demonstrate exposure to the intracanalicular vestibular schwannoma. PA indicates porus acusticus. A is reproduced with permission from the University of Rochester.

The TL allows adequate exposure of the IAC and PF with minimal brain retraction. The RS approach may be preferred if a large PF component is present. Due to the complete loss of hearing, TL is reserved only for patients with unserviceable hearing or poor hearing prognosis.

**Retrosigmoid Craniotomy**

RS is a posterior approach that allows panoramic visualization of the CPA (Fig 3). Following a suboccipital craniotomy posterior to the sigmoid sinus, the cerebellum is retracted medially, exposing the CPA mass and neurovascular structures (Fig 3). The facial nerve is identified, and the CPA component is dissected. The intrameatal component can then be accessed and removed by drilling the posterior meatal lip (Fig 3). Tumor infiltration of the cochlear nerve, poor preoperative hearing, and larger tumor size decrease the likelihood of hearing preservation.

RS permits resection of large extrameatal and small medial intrameatal tumors while allowing hearing preservation. The RS approach to intrameatal VS can be limited by a high-riding jugular bulb or obstructed by the labyrinth. Cerebellar retraction may lead to parenchymal injury. Early postoperative headaches following RS may be higher than in TL, possibly secondary to subarachnoid bone dust dissemination or the use of a titanium plate.

**Middle Fossa Approach**

The MF is a lateral approach to the IAC (Fig 4). A temporal craniotomy is performed above the external auditory canal (Fig 4). The dura is elevated off the skull base, and the temporal lobe is retracted superiorly. Landmarks for this approach include the arcuate eminence and the greater superficial petrosal nerve. The IAC can then be accessed from above (Fig 4), and the tumor can be resected following microdissection of the facial and cochlear nerves. Bone wax is used to fill exposed mastoid air cells.

The MF is best for small lateral IAC tumors, particularly those that extend to the IAC fundus, when hearing preservation is a treatment objective. MF is not typically attempted on tumors with a >1-cm CPA component due to limited exposure to the PF, though some surgeons have had success with larger tumors via
this approach. Temporal lobe retraction is associated with a small risk of seizures, aphasia, and stroke. MF is optimal for a VS arising from the superior division, which displaces the facial nerve anteriorly.

**Radiation Therapy**

Radiation can be performed by using SRS, stereotactic radiation therapy, and conventional fractionated radiation therapy. SRS is the most commonly used technique and converges multiple beams onto a delineated volume by using cross-sectional imaging to minimize injury to adjacent tissues. An initial SRS dosage of a 16- to 20-Gy marginal dose achieved a 98% tumor control rate but resulted in unacceptably high rates of early hearing loss (60%) and facial and trigeminal neuropathies (33%).

SRS dose reductions from 13–14 to 11–12 Gy in more recent years have resulted in >90% tumor control rates and <1% risk for permanent facial nerve palsies. Slightly lower doses of 12–13 Gy can be preferentially given to patients with serviceable hearing, and slightly higher doses of 13–14 Gy, to patients with poor hearing prognosis.

While hearing preservation rates of 60%–70% were initially reported, longer term follow-up studies of up to 10 years revealed progressive hearing deterioration in most patients. Serviceable hearing was preserved in only 23%–24% patients at 10 years. Older age, larger tumors, and poorer pretreatment hearing were found to be risk factors for progressive posttreatment hearing loss. Reducing the cochlear dose to improve hearing preservation continues to be controversial and has not been confirmed to reduce long-term hearing deterioration.
Observation

Observation is offered to select patients who are typically followed with serial MR imaging every 6–12 months. Indications include patients older than 60 years of age with significant comorbidity, small tumor size, and absence of symptoms. Patients who are at risk for hearing loss from other causes or prefer observation may also be offered conservative management. Observation, however, is associated with progressive hearing loss, due to the slow growth of most of these tumors. Tumor growth of 2.5 mm/year is associated with higher rates of hearing deterioration compared with slower growing tumors. If hearing preservation remains a treatment objective, earlier intervention may lead to a better outcome.

Imaging

Differential. VS is the most common extra-axial CPA mass (70%–80%), followed by meningiomas (10%–15%) and epidermoid cysts (5%). CPA meningiomas are dural-based enhancing masses that grow along the petrous ridge and can extend into the IAC. Large meningiomas are often located asymmetrically relative to the IAC (Fig 5). Meningiomas may contain intraslesional calcifications, and a dural tail and can result in changes of the underlying bone, as well as peritumoral vasogenic edema if mass effect is present.

Other enhancing lesions of the IAC and CPA include neoplastic etiologies, such as leptomeningeal metastasis, lymphoma, meningeal melanocytoma, or malignant melanoma; facial nerve perineural spread; inflammatory processes, such as Bell palsy and neurosarcoiroidosis; and aneurysms (Fig 5). Identifying enhancement of the labyrinthine facial nerve can distinguish CN VII pathologies from a VS (Fig 5). Aneurysms demonstrate nodular enhancement but are contiguous with vascular structures and often exhibit flow voids, eccentric peripheral enhancement, and pulsation artifacts on MR imaging.

Because a VS can contain cystic components, the radiologist should also be aware of other cystic lesions of the CPA. The characteristic MR signal and enhancement patterns of these lesions, however, should not lead to any confusion among these entities. Epidermoid cysts are nonenhancing cysts of congenital ectodermal elements that encase or displace neurovascular structures and extend into the cerebellar fissures with ill-defined margins. Relative to CSF, these cysts demonstrate similar attenuation on CT, isointense-to-slightly hyperintense signal to CSF on T1WI and T2WI, and incomplete suppression on T2 FLAIR. The presence of
calcifications. Unlike a meningioma, a VS does not have isoattenuating relative to the cerebellar parenchyma and typically small intracanalicular tumors can be missed. On CT, a solid VS is the IAC (Fig 6), which may reflect tumor aggressiveness.53

the IAC, brain stem and cerebellar compression, peritumoral edema, and tonsillar herniation.55 Surgical intervention is favored over SRS in the management of cystic VS because cystic VSs may respond poorly and unpredictably to SRS.56,57 In 1 study, 6.4% of cystic VSs initially treated with radiation therapy required surgical intervention.57

demonstrates avid enhancement on postcontrast T1WI (Fig 6). A secondary enhancement may extend into the modiolus (Fig 6). Enhancement may extend into the modiolus.55

diffusion restriction differentiates epidermoid from arachnoid cysts, which follow CSF signal on all sequences. Arachnoid cysts do not enhance, and they displace rather than engulf adjacent structures. Other uncommon cysts include dermoid cysts, neurocysticercosis, and neuroenteric cysts.

Initial Assessment. CT can detect moderate-large VSs, though small intracanalicular tumors can be missed. On CT, a solid VS is isoattenuating relative to the cerebellar parenchyma and typically enhances. Unlike a meningioma, a VS does not have calcifications.

CT is advantageous in assessing bony anatomy and pathologic changes. Unlike meningiomas, a moderate-large VS tends to expand the IAC (Fig 6), which may reflect tumor aggressiveness.53 IAC expansion is associated with poorer preoperative hearing and postoperative hearing function.53 Because the cochlear nerve is often located anterior or inferior to the tumor, larger tumors extending in this direction may encapsulate, infiltrate, or stretch the nerve.57,53 The facial nerve can be affected by anterior extension of the tumor, though it appears to be more resilient than the cochlear nerve.53

Due to superior contrast resolution, MR imaging is now the standard of care in evaluating VS. A sample MR imaging protocol used in the evaluation of CPA masses is included in Table 2. VS is typically T1 isointense relative to the cerebellar parenchyma and demonstrates avid enhancement on postcontrast T1WI (Fig 6). A VS may contain intralesional hemorrhage, which may exhibit T1 hyperintense signal and susceptibility artifacts on T2* gradient-echo sequences. A larger VS often demonstrates inhomogeneous enhancement secondary to intralesional hemorrhage and cysts. Concerning features include larger size, brain stem or cerebellar compression, peritumoral edema, hydrocephalus, and tonsillar herniation (Fig 6). Enhancement may extend into the modiolus secondary to cochlear infiltration (Fig 7), which decreases the rate of hearing preservation.

Cystic VSs are a subtype that accounts for approximately 10% of all VSs and are associated with higher degrees of hearing loss.54 VS cysts are thought to arise from recurrent microbleeding or osmosis-induced expansion of CSF trapped in arachnoid tissue,54 leading to T2 hyperintense signal and variable T1 signal (Fig 7). Enhancement of the cyst wall differentiates a cystic VS from an arachnoid or epidermoid cyst, the latter of which demonstrates diffusion restriction. Cystic VS may rapidly expand, leading to brain stem and cerebellar compression, edema, and hydrocephalus.55 Surgical intervention is favored over SRS in the management of cystic VS because cystic VSs may respond poorly and unpredictably to SRS.56,57 In 1 study, 6.4% of cystic VSs initially treated with radiation therapy required surgical intervention.57

**Table 2: A sample MR imaging protocol for the evaluation of VS**

<table>
<thead>
<tr>
<th>Sequence</th>
<th>FOV (cm)</th>
<th>Thickness and Spacing (mm)</th>
<th>TR (ms) (or Flip Angle)</th>
<th>TE (ms)</th>
<th>Matrix</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sag T1 FLAIR</td>
<td>24</td>
<td>5 × 1</td>
<td>2800</td>
<td>9</td>
<td>320 × 224</td>
<td>(T1 858 ms)</td>
</tr>
<tr>
<td>Ax DTI</td>
<td>26</td>
<td>3 × 0</td>
<td>8000</td>
<td>Min</td>
<td>128 × 128</td>
<td>With Ax and Cor reformations</td>
</tr>
<tr>
<td>Sag 3D T2 FLAIR FS</td>
<td>27</td>
<td>1.4</td>
<td>7600</td>
<td>120</td>
<td>256 × 256</td>
<td>Alternative to 3D T2 FLAIR (T1 = 2250 ms)</td>
</tr>
<tr>
<td>Ax T2 FLAIR</td>
<td>24</td>
<td>5 × 1</td>
<td>9500</td>
<td>125</td>
<td>352 × 224</td>
<td>Through PF only</td>
</tr>
<tr>
<td>Ax T2 FS</td>
<td>18</td>
<td>3 × 0.5</td>
<td>4917</td>
<td>87</td>
<td>320 × 320</td>
<td>With Ax and Sag oblique reformations</td>
</tr>
<tr>
<td>Ax FIESTA</td>
<td>18</td>
<td>0.8</td>
<td>(45°)</td>
<td>Min</td>
<td>300 × 300</td>
<td>Optional</td>
</tr>
<tr>
<td>Ax SWAN or SWI</td>
<td>25</td>
<td>2</td>
<td>Min (5°)</td>
<td>25</td>
<td>320 × 224</td>
<td>With Ax and Cor reformations</td>
</tr>
<tr>
<td>Sag 3D T1 FS + C</td>
<td>25</td>
<td>1.2</td>
<td>600</td>
<td>Min</td>
<td>288 × 288</td>
<td>For treatment planning; nonangled orthogonal Ax</td>
</tr>
<tr>
<td>Ax 3D SPGR + C</td>
<td>25</td>
<td>1.5</td>
<td>(20°)</td>
<td>Min</td>
<td>320 × 224</td>
<td>Alternative to 3D T1 FS + C (TI = 111 ms)</td>
</tr>
<tr>
<td>Ax T1 FS + C</td>
<td>18</td>
<td>3 × 0.5</td>
<td>2723.5</td>
<td>22</td>
<td>320 × 320</td>
<td>Alternative to 3D T1 FS + C (TI = 111 ms)</td>
</tr>
<tr>
<td>Cor T1 FS + C</td>
<td>18</td>
<td>3 × 0.5</td>
<td>2475</td>
<td>Min</td>
<td>383 × 224</td>
<td>Alternative to 3D T1 FS + C</td>
</tr>
</tbody>
</table>

Note: —SPGR indicates echo-spoiled gradient echo; FS, fat suppression; C, contrast; Sag, sagittal; Ax, axial; Cor, coronal. SWAN, T2 star-weighted angiography; Min, minimum.

* Except for the axial 3D SPGR + C, all sequences are referenced to the anterior/posterior commissure line. An axial T2 FLAIR can be performed instead of the sagittal 3D T2 FLAIR. An axial and coronal T1 FS + C can be performed in lieu of a sagittal 3D T1 FS + C.
Cystic VSs are considered more aggressive, with shorter symptomatic periods before presentation. They may surround and adhere to neurovascular structures as well as the more hypervascular solid component of the mass, leading to a less favorable surgical outcome. Subtotal resection of cystic VS is sometimes advocated, particularly if there are peripherally located thin-walled cysts, which should be emphasized in radiologic reporting (Fig 8).

High-resolution volumetrically acquired steady-state gradient-echo (3D SS-GRE) sequences with heavily T2-weighted signal provide exquisite detail of the location and morphology of the mass, the presence of decreased labyrinthine signal, the course of neighboring CNs in relation to the mass, and the relationship of the labyrinth to the posterior meatal lip. Identifying CSF lateral to an intracanalicular mass near the IAC fundus on 3D SS-GRE or contrast-enhanced T1WI is a favorable prognostic finding because involvement of the IAC fundus is associated with decreased rates of hearing preservation (Fig 7). Decreased labyrinthine signal of 3D SS-GRE on initial imaging is associated with lower rates of posttreatment hearing preservation (Fig 8).

Sagittal-oblique reformations of 3D SS-GRE sequences allow detailed assessment of the facial nerve course relative to a mass. A VS arising from the superior division of the vestibular nerve will often displace the facial nerve anteriorly, whereas one arising from the inferior division will displace the facial nerve more superiorly. The location of the facial nerve in relation to the VS influences the surgical approach chosen. Facial nerves that are displaced superiorly by the VS may be more easily injured with a TL or MF approach, leading the surgeon to favor the RS.

Because the posterior meatal lip is drilled to access the IAC in the RS approach, this region is carefully evaluated preoperatively by either CT or MR imaging. Pneumatized air cells in this region may lead to a postsurgical CSF fistula. A high-riding jugular bulb or jugular bulb diverticulum within the posterior meatal lip may potentially lead to vascular injury. Portions of the labyrinthine lying medial to the fundus–sinus line (the line from the sigmoid sinus to the IAC fundus) pose a higher risk for fenestration than those located laterally.

An abbreviated noncontrast MR imaging with 3D SS-GRE has been proposed as an inexpensive screening examination to exclude an IAC mass. This study reported 100% sensitivity with high specificity and advocated adding a coronal T2WI to reduce false-positive/negative examination findings secondary to volume averaging and banding artifacts, which could occur if relying solely on 3D SS-GRE. An abbreviated noncontrast screening MR imaging, however, may not identify etiologies that are better depicted with contrast-enhanced MR imaging, such as other neoplastic and inflammatory conditions discussed above.

Increased labyrinthine T2 FLAIR hyperintense signal has been detected in patients with various pathologies, including VS, meningiomas, Menière disease, Ramsay Hunt syndrome, otosclerosis, and sudden idiopathic sensorineural hearing loss. The T2 FLAIR hyperintense cochlear signal in patients with VS is attributed to increased pro-
tein content within the perilymph, which may be secondary to tumor compression of the cochlear nerve, resulting in interference with neuroaxonal transport of proteins. 3D-FLAIR sequences can optimally detect cochlear T2 FLAIR hyperintense signal. Kim et al. reported a significant correlation between the T2 FLAIR hyperintense cochlear signal and the degree of hearing impairment in patients with intracanalicular VS. This retrospective study, however, did not specify whether the 3D-FLAIR sequence was performed consistently before or following intravenous contrast administration. Two smaller retrospective studies reported no correlation and a weak correlation between postcontrast T2 FLAIR hyperintense signal and the level of hearing impairment in patients with VS. Additional studies should be performed to further clarify the significance of the T2 FLAIR hyperintense cochlear signal in VS.

**Follow-Up Assessment**

Objectives of follow-up imaging include identification of residual/recurrent tumor, assessment of tumor size, response to radiation therapy, and the presence of posttherapeutic complications. Residual tumor is best assessed with a fat-suppressed contrast-enhanced T1WI, because the signal from fat packing can be nullified (Fig 2). Because the goals of therapy have shifted from total resection to functional preservation, residual tumor is often intentionally left behind in areas near the facial nerve. The presence of residual enhancing tumor is not uncommon and may be followed with serial imaging and further treated with SRS (Fig 3). A residual mass tends to contract and become more rounded within 6–12 months of completion of SRS.

Standardized methods of tumor reporting and measurements have been promoted by national organizations, such as the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) in 1995 and the Consensus Meeting on Systems for Reporting Results in Acoustic Neuroma in 2003, though no single method has been clearly adopted. VS should be described as intracanalicular, extrameatal, or intrameatal and extrameatal, and cross-sectional measurements should be specific for each component. Growth tends to be the greatest in the extrameatal component, and recommendations have focused on the extrameatal measurements. The AAO-HNS has recommended the square root product of the extrameatal anteroposterior × medial lateral diameters, with the anteroposterior diameter measured parallel to the petrous ridge. The Consensus Meeting in 2003 favored using the maximum extrameatal diameter, which, by itself, sufficiently reflected growth of the tumor. One study has found the AAO-HNS methodology to be preferable because tumors tend to grow in both anteroposterior and ML directions. Immediately following SRS, the tumor may increase in size due to intraslesional edema, which rarely indicates treatment failure. In 1 study, 5% of tumors enlarged following SRS but remained stable on subsequent imaging. Most VSs treated with SRS will subsequently decrease or remain stable in size, reflecting adequate tumor control. Decreased enhancement centrally within the tumor is considered a positive response to therapy and is typically seen within 6 months following SRS (Fig 9). Radiation therapy may uncommonly induce cystic degeneration that may be secondary to microbleeding, increased vascular permeability, or scarring of arachnoid adhesions (Fig 9). The potential for postradiation cystic degeneration is one rationale for treating cystic VS initially with surgical resection.

While uncommon, dural sinus thrombus may be seen following an RS or TL approach secondary to injury of the sigmoid sinus and may result in venous congestion or infarction. Brain retraction during an RS or MF approach may result in edema or ischemia of the cerebellum or temporal lobe, respectively. Postoperative infection may result in meningitis or, if severe, cerebritis. CSF leak can sometimes be detected by identifying the presence of a fluid collection within or subjacent to the craniotomy site. Other complications such as CN deficits are better assessed by clinical examination.

Labyrinthine fenestration may present with postoperative hearing loss and can be evaluated with a dedicated CT of the temporal bones. Bony labyrinthine dehiscence, however, may not always correlate with hearing loss or vestibular symptoms. Decreased T2 signal within the vestibulocochlear complex on 3D SS-GRE imaging postsurgically may reflect membranous fenestration, microvascular injury to the cochlea, or labyrinthitis ossificans. The decrease in T2 signal has been correlated with postoperative hearing loss.

**CONCLUSIONS**

VSs are benign neoplasms of the vestibulocochlear nerve sheath and are the most common CPA tumor. VS can be managed by surgical resection, radiation therapy, and observation, though only select patients are followed conservatively due to its association with hearing loss. The treatment objectives of VS have shifted from total resection to long-term tumor control with maximum functional preservation. Larger tumors of >3 cm are generally surgically resected because radiation poses a risk of brain stem compression due to posttreatment edema. Smaller tumors may be treated with surgery or radiation. Lateral skull base approaches include the TL, RS, and MF and have been applied to other skull base and PF pathologies. Knowledge of the management options and objectives allows the radiologist to provide imaging findings pertinent to initial management and to recognize posttherapeutic findings and unexpected complications.

**ACKNOWLEDGMENTS**

We thank Nadezhda Kiriyak and Gwen Mack for their illustrations in this article.

44. Flickinger JC, Kondziolka D, Lansford LD. Dose and diameter relationships for facial, trigeminal, and acoustic neuropathies following acoustic neuroma radiosurgery. Radiother Oncol 1996;41:215–19 CrossRef Medline
46. Roos DE, Potter AE, Zacest AC. Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time. Radiother Oncol 2013;101:620–24 CrossRef Medline
of 440 patients more than 10 years after treatment with gamma knife surgery. J Neurosurg 2013;118:557–65 CrossRef Medline
52. Sarrazin JL. Infra tentorial tumors [in French]. J Radiol 2006;87:748–63 Medline